Clinical trials: Hematological Disease
Multiple Myeloma
Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation
The purpose of this study is to learn about possible changes in thinking (cognitive) abilities, such as memory skills, and in brain anatomy and function, in adults with multiple myeloma who are treated with high-dose chemotherapy…
- Trial name
- NCT03508765
- Testing
- Structural Image, Functional Image, Digit Span subtest
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Myelodysplastic Syndrome
Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies
The purpose of this study is to find a safe dose of actinium-225 when it is labeled to HuM195. This will be done with a "phase I trial," in which a preset schedule of doses gets more powerful for each new group of patients as the…
- Trial name
- NCT00672165
- Testing
- ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL.
- Conditions
- Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia
- Trial name
- NCT05885464
- Testing
- BEAM-201
- Where
- 10 sites in United States
- Volunteers
- 5 people
- Sponsor
- Beam Therapeutics Inc.
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation
The purpose of this trial is to test the safety and immune response to four immunizations with this vaccine made from a protein produced by the patient's tumor.
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00002787
- Testing
- autologous immunoglobulin idiotype-KLH conjugate vaccine, sargramostim, aldesleukin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Multiple Myeloma
Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.
To evaluate the safety and tolerability of intravenous zoledronic acid in the treatment of patients with multiple myeloma stage III with bone lesions related to Cancer.
- Trial name
- NCT00242528
- Testing
- Zoledronic acid
- Sponsor
- Novartis
Anemia
Timing of Cord Clamping and Neonatal Hemoglobin
The purpose of this study is to determine whether the timing of the clamping of the umbilical cord after delivery has an impact on neonatal hemoglobin and hematocrit, tests that determine the number of red cells in the blood and…
- Trial name
- NCT00371228
- Testing
- Delay of umbilical cord clamping
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Oklahoma State University Center for Health Sciences
Multiple Myeloma
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with cevostamab in participants with relapsed/refractory multiple myeloma (R/R MM) who have received a…
- Trial name
- NCT05646836
- Testing
- Cevostamab, XmAb24306, Tocilizumab
- Where
- 13 sites in Australia, Denmark and 5 more
- Volunteers
- 90 people
- Sponsor
- Genentech, Inc.
Eosinophilic Asthma
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
The primary objective of the study is to characterize the efficacy of reslizumab treatment, at a dosage of 3.0 milligrams per kilogram (mg/kg) every 4 weeks for a total of 4 doses, in improving pulmonary function in relation to…
- Trial name
- NCT01508936
- Testing
- Reslizumab
- Where
- 66 sites in United States
- Volunteers
- 511 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Varus-Derotation Osteotomy Surgery, Iron-deficiency Anemia
Pediatric Outcomes and Recovery With Peri-Operative Iron Supplement Evaluation
Varus-derotation osteotomy (VDRO) is a surgery to prevent or address hip displacement in children. Many children having this surgery have cerebral palsy or other neuromotor disorders, who have a higher rate of malnutrition…
- Conditions
- Varus-Derotation Osteotomy Surgery, Iron-deficiency Anemia, Pelvic Osteotomy Surgery, Cerebral Palsy
- Trial name
- PORPOISE (NCT07095244)
- Testing
- Iron Supplement, Comprehensive Nutrition Management
- Where
- Canada
- Volunteers
- 180 people
- Sponsor
- University of British Columbia
Sickle Cell Anemia, Retinopathy
Ranibizumab for Neovascularization in Sickle Cell Retinopathy
The purpose of this study is to determine the ocular and non-ocular safety of a single dose of ranibizumab in treating neovascularization secondary to sickle cell retinopathy.
- Trial name
- NCT00618644
- Testing
- Ranibizumab
- Where
- United States
- Sponsor
- Kresge Eye Institute
Advanced Solid Tumor, Non Hodgkin Lymphoma
A Study of BTX-1188 in Subjects With Advanced Malignancies
This is a multicenter, open label, nonrandomized, sequential dose escalation, multiple dose study designed to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-1188 orally…
- Conditions
- Advanced Solid Tumor, Non Hodgkin Lymphoma, Acute Myeloid Leukemia
- Trial name
- NCT05144334
- Testing
- BTX-1188
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Biotheryx, Inc.
Hypofibrinogenemia, Afibrinogenemia
Human Fibrinogen Concentrate in Pediatric Cardiac Surgery
The goal of the study is to determine whether the use of Human Fibrinogen Concentrate (RiaSTAP) will decrease blood loss and the need for component blood therapy in neonates and infants undergoing cardiopulmonary bypass.
- Conditions
- Hypofibrinogenemia, Afibrinogenemia, Bleeding Disorders
- Trial name
- RiaSTAP (NCT02822599)
- Testing
- RiaStAP, Saline
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Childhood Langerhans Cell Histiocytosis, Leukemia
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
RATIONALE: Umbilical cord blood or placental blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.
- Conditions
- Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00008164
- Testing
- umbilical cord blood transplantation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Ublituximab + Ibrutinib in Select B-cell Malignancies
The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with Ibrutinib in patients with advanced hematologic malignancies.
- Trial name
- NCT02013128
- Testing
- Ublituximab, Ibrutinib
- Where
- 18 sites in United States
- Volunteers
- 66 people
- Sponsor
- TG Therapeutics, Inc.
Leukemia, Myelocytic, Acute
AML Treatment in Untreated Adult Patients
The present therapy intends to be an homogeneous treatment for AML patients based on a pretreatment with hydroxiurea plus an induction therapy with the standard arm with Daunorubicine as according to EORTC-GIMEMA AML10 study.
- Trial name
- LAM99P (NCT00449319)
- Testing
- Identification of appropriate therapies according to risks factors, Daunorubicine, Transplant
- Where
- 36 sites in Italy
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Lymphocytic Leukemia, Chronic
A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia
This multi-center, open-label, dose-finding study will evaluate the safety and pharmacokinetics as well as the preliminary efficacy of venetoclax (GDC-0199; ABT-199) administered in combination with obinutuzumab to participants…
- Trial name
- NCT01685892
- Testing
- Obinutuzumab, Venetoclax
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 82 people
- Sponsor
- Genentech, Inc.
Myeloid Malignancy, Myeloid Malignancies
MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies
This research study is evaluating the feasibility of conducting cancer genetic testing using healthy skin cells among participants with a diagnosis of a blood cancer.
- Conditions
- Myeloid Malignancy, Myeloid Malignancies, Blood Cancer, Blood Cancers
- Trial name
- NCT06543511
- Testing
- Genetic Blood Test
- Sponsor
- Dana-Farber Cancer Institute
Acute Myelogenous Leukemia
Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia
This is a phase Ib study with a 3 + 3 dose escalation design followed by a dose-expansion phase.
- Trial name
- PAVE (NCT04172844)
- Testing
- Azacitidine, Venetoclax, Pevonedistat
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Medical College of Wisconsin
Myelofibrosis
Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis
This study is to determine the efficacy of Jaktinib versus Hydroxycarbamid in participants with Intermediate-2 or High-risk myelofibrosis
- Trial name
- NCT04617028
- Testing
- Jaktinib, Hydroxycarbamide Tablets
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Hyperbilirubinemia, Erythroblastosis, Fetal
Efficacy of High-dose Intravenous Immunoglobulin Therapy for Hyperbilirubinemia Due Rh Hemolytic Disease
The use of intravenous immunoglobulin G (IVIG) therapy has been reported in hyperbilirubinemia of Rh hemolytic disease but we don't have enough evidences for it.
- Trial name
- NCT00288600
- Testing
- Intravenous Immunoglobulin, Normal saline solution
- Where
- Brazil
- Volunteers
- 92 people
- Sponsor
- Oswaldo Cruz Foundation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.